An observational study in Chronic Lymphocytic Leukemia, sponsored by Astellas Pharma Europe B.V.. Completed at 34 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-06.
Sponsored by Astellas Pharma Europe B.V. · Observational
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 190 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →Astellas Pharma Europe B.V. is the lead sponsor of 93 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with В-cell chronic lymphocytic leukemia under the care of a physician in the haematology/chemotherapy departments in 20-25 centers in the Russian Federation
Exclusion Criteria:
Other: bendamustine · Other: rituximab
Routine practice
Also known as: Ribomustin
Routine practice
Also known as: Mabthera
Overall response rate
Time frame: Within 60-90 days after end of treatment
Adverse drug reactions
Time frame: At all post-treatment visits (up to 30 days after end of treatment)
Treatment Failure (TF)
Time frame: Within 60-90 days after end of treatment
Time to Progression (TTP)
Time frame: 60 months
Progression-Free Survival (PFS)
Time frame: 60 months
Relapse following complete or partial remission
Time frame: 60 months
Overall survival
Time frame: 60 months
Quality of Life of patients receiving Ribomustin therapy
Time frame: At all post-treatment visits (up to 30 days after end of treatment)
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astellas Pharma Europe B.V.